Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab in advanced cervical cancer
NCT06755515Phase 3Enrolling by invitation
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rulonilimab in Cervical Cancer (CC), sponsored by Shandong New Time Pharmaceutical. Started Sep 2024; status: enrolling by invitation.
02
Drugs
rulonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06755515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06755515.